Read more about the article Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
A shutter shock image file of 131812463 with dna like image

Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million

GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency of the US government's Department of Health and Human Services'…

Continue ReadingChrysalis BioTherapeutics Receives BARDA Contract for Over $10 million
Read more about the article Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508
A shutter shock image file of 131812463 with dna like image

Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508

GALVESTON, Texas, Aug. 21, 2019 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA) have granted…

Continue ReadingChrysalis BioTherapeutics Granted Orphan Drug Status for TP508